Innate Immunotherapeutics Limited (ASX Code:IIL) has received 'open label access' requests from more than 90% of patients who have now completed the Company's Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). The 12 month randomised, placebo- controlled, double-blind trial completed the enrolment of 93 patients in April 2016. The last patient in the trial is expected to complete all study related visits in early May 2017 and the clinical study report is expected about four months later.
To date the Company has received requests from 44 patients who want access to MIS416 now that they have completed (or are about to complete) the Company's Phase 2B trial. As part of gaining ethics approvals to conduct the 2B trial in Australia, the Company undertook to make MIS416 available to all patients who completed the study and who, with the support of their doctor, wanted access to the unapproved drug.
For further information please download PDF attached:
Download this document
